Equine sarcoids, part 3: association with bovine papillomavirus by Bogaert, Lies et al.
Vlaams Diergeneeskundig Tijdschrift, 2008, 78 Theme: Equine sarcoids   131
CLASSIFICATION AND GENOME ORGANI ZA -
TION
Bovine papillomaviruses are small non-enveloped
DNA viruses (Figure 1) and are members of the family
Papillomaviridae, a large family of animal and human
viruses that normally infect epithelial cells causing
hyperproliferative lesions. To date, 8 BPV types (BPV-
1-8) have been characterized and classified into 3
genera: the Delta-, Epsilon- and Xi-papillomaviruses
(de Villiers et al., 2004). BPV-1 and -2 belong to the
Delta-papillomaviruses and induce fibropapillomas
(warts). BPV-3, -4 and -6 are members of the Xi-
papillomaviruses and infect only the epithelium,
inducing true papillomas. BPV-5 and -8 belong to the
Epsilon-papillomaviruses and cause both fibro papil -
lomas and epithelial papillomas (Bloch et al., 1994b;
Tomita et al., 2007). Phylogenetic analysis based on
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ABSTRACT
The genetic material of the bovine papillomavirus (BPV) can be detected in virtually all equine sarcoids.
Eight different types have been described, all inducing benign proliferation of epithelium in cattle. BPV-1 and -2
are less strictly species-specific and can induce equine sarcoids in horses. Historically, association between
BPV and equine sarcoids has been demonstrated using inoculation studies and detection of BPV DNA and BPV
gene expression. The BPV genome is composed of 6 early and 2 late genes, with E5 and E6 being the most
important transforming genes. Specific BPV-1 variants associated with equine sarcoids have been reported,
suggesting circulation of the virus between horses. In horses, a non-productive BPV infection occurs, with
only transcription of early genes, responsible for genome maintenance, regulation of cell growth and cell
transformation. There is no formation of new infectious virus particles as is the case in the natural host. 
SAMENVATTING
Het genetisch materiaal van het boviene papillomavirus (BPV) kan worden aangetoond in vrijwel alle sarcoïden.
Er worden 8 verschillende BPV-typen beschreven die alle goedaardige epitheliale proliferaties veroorzaken bij
runderen, maar enkel BPV-1 en -2 zijn minder strikt speciesspecifiek en kunnen bij paarden sarcoïden induceren. De
associatie tussen BPV en sarcoïden werd aangetoond door middel van inoculatiestudies en de detectie van BPV-
DNA en BPV-genexpressie. Het BPV-genoom is samengesteld uit 6 vroege en 2 late genen, waarbij E5 en E6 de
meest belangrijke transformerende genen zijn. Specifieke BPV-1-varianten geassocieerd met sarcoïden worden
beschreven, wat er kan op wijzen dat het virus van paard naar paard kan overgedragen worden. Bij paarden vindt een
niet-productieve infectie plaats, waarbij er enkel een transcriptie is van vroege genen die verantwoordelijk zijn voor
het onderhoud van het genoom, de celgroeiregulatie en de celtransformatie. Er is geen vorming van nieuwe
infectieuze viruspartikels zoals bij de natuurlijke gastheer.
Figure 1. Electron microscopic picture of human
papillomavirus particles (Stanley et al., 2006).
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the complete L1 ORF suggests that BPV-7 should be
classified in a novel genus (Ogawa et al., 2007).
BPV has a genome of 7900 bp of double-stranded
DNA and contains 6 early and 2 late genes (Chen et
al., 1982; Campo, 1988) (Figure 2). Early genes (E1,
E2, E4, E5, E6 and E7) are responsible for replication
and transformation, whereas late genes (L1 and L2)
encode the structural proteins. The early and late
regions are separated by a stretch of non-transcribed
DNA, called the long control region (LCR), which
contains the transcriptional promotors and enhancers,
the origin of DNA replication and binding sites for
numerous cellular transcription factors as well as for
the virally encoded early gene product E2 (McBride
et al., 1991; Phelps et al., 1999; Chambers et al.,
2003a). 
The most extensively studied BPV gene is E5,
which plays a prominent role in sarcoid development.
E5 is a small hydrophobic protein, consisting of 44
amino acids, residing in the membranes of the Golgi
apparatus and the endoplasmic reticulum. In vitro
studies on murine fibroblasts have shown that BPV E5
is one of the most important genes in neoplastic
transformation of the cell (Marchetti et al., 2002). As
soon as E5 is expressed, a rapid transformation occurs
without the help of other proteins. E5 contributes to
cellular transformation of fibroblasts in different ways.
It has been shown to induce activation of the platelet-
derived growth factor ß (PDGF- ß) receptor by binding
to it (Petti and DiMaio, 1992; DiMaio and Mattoon,
2001). Activation of PDGF- ß receptors of the dermal
fibroblasts by E5 results in mitogenesis in nearby
epithelial cells (Carr et al., 2001b). This event may
explain the typical pseudoepitheliomatous hyperplasia.
Furthermore the vacuolar H+-ATPase is targeted by
BPV E5 (Ashrafi et al., 2002; Marchetti et al., 2002).
This proton pump is essential for the function of
cellular compartments that process growth factors. By
binding of E5, an alteration in this process occurs. The
acidification of the endosomes is blocked and
degradation of the receptors for growth factors is
inhibited resulting in a prolonged stimulation time,
besides an increased receptor recycling (Carr et al.,
2001b). This hypothesis is objected by the findings of
Ashbey et al. (2001) who found no alteration in the
function of the vacuolar H+-ATPase. The latter authors
suppose that the binding to the vacuolar H+-ATPase
has only a transport function in the cell in order to
reach other intracellular targets. The BPV E5 also
binds to16K ductin/subunit c, a component of the gap
junctions, responsible for the contact between
neighboring cells. Through this binding, the contact is
disrupted and the transformed cell can replicate
uncontrolled (Campo, 1997). Interaction with 16K
leads also to the alkalinization of the endosomes and
the Golgi apparatus with consequent intracellular
retention of MHC class I molecules (Ashrafi et al.,
2002; Marchetti et al., 2002). The absence of MHC
class I on the cell surface would help the infected cells
to evade host immunosurveillance (Chambers et al.,
2003a). 
The BPV E6 protein is localized in membrane and
nuclear fractions and contains 2 highly conserved zinc
finger domains typical of DNA-binding transcription
activator proteins. However, cell transformation by E6
seems to be independent of its transcription
transactivation function (Ned et al., 1997). Human
papillomavirus (HPV) E6, the most important
transforming protein of HPV, is known to bind to p53
and subsequently stimulate its degradation (Scheffner
et al., 1990). However, BPV E6 does not bind to p53
(Rapp et al., 1999). Instead, the transformational
ability of BPV E6 is linked to its ability to bind ERC-
55/E6BP, a calcium binding protein (Chen et al., 1995)
and in part CBP/p300, a transcriptional co-activator
(Zimmermann et al., 2000) which interferes with the
normal cell functions. BPV E6 also binds the focal
adhesion protein paxillin (Tong et al., 1997; Tong and
Howley, 1997; Vande Pol et al., 1998) and the γ
subunit of the clathrin adaptor complex AP-1 (Tong et
al., 1998) leading to disruption of cytoskeleton and
vesicular traffic pathways. The cytoskeleton is vital for
the maintenance of cellular morphology, motility,
division and cell-cell and cell-matrix interactions and
the AP-1 complex plays an important role in the
control of cell proliferation and differentiation
(Chambers et al., 2003a). 
The function of the other early BPV genes is less
well studied, but it has been established that E1 is
responsible for initiation of replication and
maintenance of the genome. E2 is, besides its role in
replication, an important regulator of transcription.
The exact role of E4 is still unknown, but its functions
suggest a role in facilitating and supporting viral
genome amplification, the regulation of late gene
expression, control of virus maturation and mediation
of virus release (Roberts, 2006). E7 has a minor role in
cell transformation and is a regulator of the BPV copy
number (Campo, 1988). This genome organization is
somewhat different from the epitheliotropic BPVs
(BPV-3, -4 and -6) which lack the E6 gene. Instead
Figure 2. Genome organisation of papillomaviruses
(Muñoz et al., 2006).
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they have an E5 (formerly defined as E8) ORF
between E7 and the LCR on the genome (Campo,
1992; Morgan and Campo, 2000). Also in HPV a
different organization is seen, where E6 and E7 are the
most important transforming genes, and E5 is only
active in the early stages of neoplastic transformation
(Blair et al., 1998).
Specific BPV-1 variants associated with equine
sarcoids have been reported. Most variation in
nucleotide sequences of papillomaviruses in general is
found in the transforming genes E5, E6 and E7.
Chambers et al. (2003b) found 7 E5 sequence variants
in 34 sarcoids, none of them identical to the prototype
sequence found in cattle, which might reflect the
specific clinical presentation of equine sarcoids. On
the other hand, E1 and E2 have a more conserved
sequence, probably due to strict conditions for
replication and transcription (Chan et al., 1992; Nasir
et al., 2007). LCR variants of sarcoid BPV-1 with a
higher activity in equine cells compared to bovine cells
have been identified suggesting that these BPV
variants have an enhanced function in equine sarcoids
(Nasir et al., 2007). These findings suggest that
sarcoids are associated with variant BPV-1 genomes
that preferentially infect horses and are maintained
within equids (Nasir et al., 2007).
PAPILLOMAVIRUS INFECTION IN THE
NATURAL HOST
Natural infection with papillomaviruses occurs in
epithelial cells and induces benign, self-limiting
cutaneous and mucosal proliferations, called “warts”.
During acute virus infection, replication of the virus
genome is strictly linked to the state of differentiation
of the infected cell. The virus initially infects the basal
keratinocytes. The early genes are then expressed in
the undifferentiated basal and suprabasal layers. Viral
DNA is replicated in the differentiating spinous and
granular layers and expression of the late structural
proteins is limited to the terminally differentiated cells
of the squamous layer, where the new virus particles
are encapsidated and released into the environment as
the cells shed (Chambers et al., 2003a). 
In cattle, mainly young animals are affected; later
on they acquire immunity so that older animals rarely
develop warts (Nicholls and Stanley, 2000). Initially
transformation of subepithelial fibroblasts is seen,
followed by epithelial acanthosis and the typical
papilloma formation. BPV-1 mainly affects the genital
region (teat and penile papillomas and the surrounding
skin), while BPV-2 can infect the entire skin surface
as well as the epithelial layers of the gastro-intestinal
tract (Jarrett, 1984; Campo, 1987; Campo, 1997). In
Europe, warts in cattle are commonly observed on the
abdomen, limbs and dorsum, whereas in the USA
mainly the head, neck and shoulders are affected
(Phelps et al., 1999). Most animals will spontaneously
cure after several weeks to months as a result of a cell-
mediated immune response. Reinfection is prevented
by neutralizing antibodies against capsid proteins. This
immunity is type specific, so infection with other BPV
types is still possible (Nicholls and Stanley, 2000).
In a small number of cases, no regression or even
malignant transformation to squamous cell carcinoma
is seen. Initiation of malignant transformation is linked
to the deregulated expression of the early virus genes,
which results in an uncontrolled proliferation and loss
of differentiation of the infected cells (Campo, 1997).
The presence of BPV-2 DNA in urinary bladder cancer
in cattle is known, both naturally as well as
experimentally induced (Campo and Jarrett, 1986;
Borzacchiello et al., 2003; Yuan et al., 2006). 
HISTORY OF ASSOCIATION BETWEEN BPV
AND EQUINE SARCOIDS
Epidemiological data suggest an etiological role of
an infectious agent in the development of equine
sarcoids (Jackson, 1936; Voss, 1969; Ragland, 1970).
Many similarities can be observed between equine
sarcoids and papillomatosis in other species: fast
growth, tendency for multiplicity and spreading over
the body by contact between different parts of the body
(Jackson, 1936). Epizootics have been described in
closed herds of horses and zebras, pointing to an
infectious agent (Ragland et al., 1966; Nel et al.,
2006). Inoculation studies conducted in the early fifties
suggested a role of BPV in sarcoid development
(Olson and Cook 1951). Nevertheless, transmission
studies from sarcoids to cattle were not successful
(Ragland et al., 1970). Other viruses, such as the
equine cutaneous papillomavirus (Gorman, 1985;
Obanion et al., 1986) and a retrovirus (England et al.,
1973; Cheevers et al., 1982), were supposed to be
involved, but later on enough evidence was collected
to assign an etiological role in equine sarcoid
development only to BPV-1 and -2 (Lancaster et al.,
1977; Angelos et al., 1991; Otten et al., 1993; Teifke
et al., 1994; Bloch et al., 1994a; Reid et al., 1994b;
Nasir et al., 1997; Nasir and Reid, 1999; Carr et al.,
2001b).
Inoculation studies
The earliest suggestion that sarcoids may have an
infectious origin was made in the early fifties. Horses
were experimentally infected with cell-free extracts
from cattle papillomas resulting in tumors grossly and
histologically mimicking equine sarcoids (Olson and
Cook, 1951). Later studies have confirmed these
findings (Ragland and Spencer, 1968; Voss, 1969;
Ragland and Spencer, 1969; Ragland et al., 1970;
Koller and Olson, 1972; Lancaster et al., 1977;
Makady et al., 1990). Yet many differences were also
observed between the induced tumors and naturally
arising sarcoids. Histologically, only the dermal layers
were changed without involvement of the epidermis
and picked fence formation was not observed.
Moreover, all induced tumors regressed spontaneously
within 4 to 12 months and neutralizing antibodies
against BPV were formed resulting in resistance
against re-infection. In natural infection, spontaneous
regression exists but is less common. Moreover, no
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neutralizing antibodies against BPV are formed and
horses remain sensitive to re-infection (Ragland and
Spencer, 1969; Lancaster et al., 1977; Brostrom et al.,
1979). Furthermore, attempts to identify BPV particles
in natural cases of equine sarcoids by electron
microscopy or using anti-BPV antibodies have been
unsuccessful (Barthold and Olson, 1978; Sundberg et
al., 1984). One reason for the observed differences
might be that with experimental inoculation numerous
viral particles as well as bovine antigens are inserted in
the organism inducing a strong immune reaction. In
natural infection, possibly only one or a few virus
particles infect the cell causing latent or non-
productive infection (Carr et al., 2001a). Moreover,
the horse is not the natural host for BPV and cannot
support the vegetative portion of the viral life cycle
(Gorman, 1985; Sousa et al., 1990). In natural sarcoids
BPV DNA is kept in a non-integrated episomal state in
the nucleus, only the early genes are transcribed and
only a few copies of the genome are produced
(Goodrich et al., 1998). This might explain why
inoculation of sensitive calves with equine sarcoid
material does not induce papillomas and why these
animals remain sensitive for BPV infection (Ragland
et al., 1970).
Detection of BPV DNA
Since the seventies, several studies have
demonstrated the presence of BPV DNA in equine
sarcoids with molecular techniques. Measurements of
DNA-DNA reassociation kinetics on fresh or frozen
material yielded 80-86 % of sarcoids positive for BPV
DNA (Lancaster et al., 1977). Southern blot
hybridization on fresh or frozen material was positive
in 86-100 % of the sarcoids (Trenfield et al., 1985;
Angelos et al., 1991; Reid et al., 1994b). PCR on
paraffin embedded material demonstrated BPV DNA
in 74-91 % of all cases (Teifke et al., 1994; Bloch et
al., 1994a) and PCR on fresh of frozen samples
resulted in a 100 % detection rate (Otten et al., 1993;
Martens et al., 2001).
An explanation for the fact that BPV DNA can
sometimes not be demonstrated in 100 % of the
examined sarcoid samples might be the insensitivity
of the technique used e.g. when only a low copy
number of viral genomes per cell is present (Angelos
et al., 1991) or after unsuited or too long formalin
fixation (Teifke et al., 1994; Bloch et al., 1994a).
Detection of BPV gene expression
Nasir and Reid (1999) demonstrated that in 95 % of
the sarcoids where BPV DNA can be detected with
PCR, expression of viral genes is also present. BPV
E2 and E5 mRNA were detected in respectively 90 %
and 80 % of the sarcoids. This was the first evidence
of direct involvement of BPV in the pathogenesis of
equine sarcoids. In additional studies, BPV E2, E5, E6
and E7 were found to be expressed in up to 100 % of
the sarcoids (Chambers et al., 2003b; Nixon et al.,
2005; Bogaert et al., 2007). Carr et al. (2001b) could
demonstrate the E5 protein in all examined sarcoids.
Collectively, these studies clearly provide evidence
that the viral genes are expressed and that the presence
of BPV DNA in equine sarcoids is not coincidental.
PATHOGENESIS OF BPV INFECTION OF THE
HORSE
Although most papillomaviruses are extremely
species- and tissue-specific, it has now been
established that a minority of them can also infect
other hosts resulting in a different pathological
outcome. BPV infection of the horse is one of the most
extensively studied species-crossing infections. Both
BPV-1 and BPV-2 infections occur, independent of
each other, but no correlation exists between BPV type
and clinical presentation of the equine sarcoid (Reid
et al., 1994b). Regional differences in frequency of
both types are observed: in Europe, 74 - 93 % of all
examined samples of sarcoids are infected with BPV-
1, compared to only 7 - 26 % BPV-2 (Angelos et al.,
1991; Otten et al., 1993; Teifke et al., 1994; Martens
et al., 2000; Martens et al., 2001; Bogaert et al., 2007).
In the USA however, both types are seen in equal
proportions (Teifke et al., 1994; Carr et al., 2001a). In
a single tumor only one BPV type has been found up
till now, but in case of multiple tumors on the same
horse, both BPV types can be demonstrated (Otten et
al., 1993; Martens et al., 2001; Carr et al., 2001a).
These findings point towards lack of immunity to
superinfection (Otten et al., 1993). In Australia, a BPV
type has been found in a small number of sarcoids
different from type 1 and type 2. Maybe this is a third
and until now unidentified type (Trenfield et al., 1985).
The number of copies of BPV DNA per diploid
equine sarcoid cell varies between 0.1 and 500
(Lancaster et al., 1977; Amtmann et al., 1980; Otten et
al., 1993; Goodrich et al., 1998; Yuan et al., 2006).
They are present in a non-integrated circular episomal
state in the cell (Amtmann et al., 1980). In situ
hybridization studies have only shown BPV DNA in
the nuclei of fibroblasts, especially at the dermo-
epidermal junction and not in the epidermis (Teifke et
al., 1994). This is in contrast with BPV infection in
cattle, where the virus is mainly located in the
epidermal layers. Only in the first stages of infection in
cattle, BPV DNA is found in the fibroblasts (Phelps et
al., 1999). Infection of BPV in a non-permissive host
results in a non-productive cycle. There is only
transcription of early genes, responsible for genome
maintenance, regulation of cell growth and cell
transformation (Gorman, 1985; Sousa et al., 1990). A
productive infection only occurs in bovine skin in
well-differentiated keratinocytes: only here consi -
derable replication and formation of complete virus
particles takes place (Campo, 1997; Carr et al.,
2001b). It has been shown that intra-type sequence
variation occurs within papillomavirus types, which
can affect the cellular location and function of viral
proteins, including E5, which in turn can affect the
pathogenesis and transforming effects of the virus
(Reid et al., 1994a; Giannoudis and Herrington, 2001;
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Chambers et al., 2003b).
When an equine fibroblast gets infected by BPV-1
or -2, a number of cellular changes can happen
resulting in cell transformation and uncontrolled
growth. First of all, the MHC involved in immune
regulation plays a major role. Other cellular proteins
are also involved, such as p53, c-myc and in Arabian
Horses DNA-PKcs, and probably many more.
The tumor suppressor gene p53 is coding for a
nuclear phosphoprotein which will activate, in case of
genetic damage, the transcription of genes inhibiting
the cell cycle progression, resulting in DNA repair
(Nasir et al., 1999). P53 inhibits expression of the
basic fibroblast growth factor and inhibits
angiogenesis by up-regulation of thrombospondin-1
(Bucher et al., 1996). These events result in
conservation of the genetic stability of the cell (Nasir
et al., 1999). In human cancers it is observed that
somatic mutation of p53 is the most commonly
observed genetic alteration (Levine et al., 1994). In
horses and donkeys with equine sarcoids this is not
observed, although a point mutation cannot be
excluded (Bucher et al., 1996; Nasir et al., 1999).
Other explanations for p53 inactivation are complex
formation with viral or cellular proteins (Nasir et al.,
1999). HPV E6 is known to bind to p53 and
subsequently stimulate its degradation (Scheffner et
al., 1990). However, BPV E6 does not (Rapp et al.,
1999). Yet it is supposed that in one way or another
function loss of p53 takes place resulting in
uncontrolled proliferation of fibroblasts and
angiogenesis (Bucher et al., 1996). Another hypothesis
is cytoplasmic sequestration of p53, leading to
inability to exert it function in the nucleus (Nasir et al.,
1999). Immunohistochemical staining has demon -
strated that 9-44 % of the sarcoids show perinuclear
staining for p53 (Martens et al., 2000; Nixon et al.,
2005; Bogaert et al., 2007). These data indicate that
nuclear exclusion seems to be a possible explanation
for the deficient p53 mechanism.
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OPROEP
Onderzoek naar equine sarcoïd
Op de Vakgroep Heelkunde en Anesthesie van de Huisdieren van de Faculteit Diergeneeskunde te Merelbeke loopt
momenteel een onderzoek naar de transmissie van het boviene papillomavirus. Hiervoor zijn we op zoek naar
proefpaarden met equine sarcoïden, evenals naar paarden die vroeger reeds behandeld werden voor sarcoïden maar
nu sarcoïd-vrij zijn. Deze paarden zullen gebruikt worden om de exacte manier van transmissie te ontrafelen, uit-
gaande van viraal materiaal afkomstig van zowel runderen als van paarden. Opgelet: deze paarden zullen worden
overgekocht door de vakgroep en kunnen dus niet in het bezit blijven van de eigenaar! Indien u in uw cliënteel der-
gelijke dieren hebt die anders toch moeten geëuthanaseerd of geslacht worden kunt u ons steeds contacteren voor
overname van deze dieren.
Contact: Pieter Depoorter (pieter.depoorter@UGent.be), Lies Bogaert (lies.bogaert@UGent.be)  
